비욘드바이오

BEY2153

Alzheimer’s and neurodegenerative disease treatment

An investigational new drug targeting amyloid and tau, proteins known to cause Alzheimer's disease

Abnormal amyloid beta plaques and tau tangles are known to be the main causes of hypomnesia and cognitive decline. BEY2153 is a novel investigational new drug that blocks both amyloid and tau.

Efficacy studies using animal and cellular models of Alzheimer’s disease showed that the drug enhances cognitive and behavioral functions and inhibits neuronal death. In particular, BEY2153 is expected to be highly effective even at low doses due to its permeability through the blood-brain barrier, thereby potentially minimizing adverse effects associated with higher doses.

BEY2153 was approved for a Phase 2 IND in Korea in January 2025 and is expected to initiate the trial soon.

In addition, BEY2153 showed strong efficacy in animal and cellular models of Parkinson’s disease and multiple system atrophy, and Phase 2 trials for these indications are being planned.